Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 225

1.

Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes.

Dorkhan M, Dencker M, Stagmo M, Groop L.

Cardiovasc Diabetol. 2009 Mar 20;8:15. doi: 10.1186/1475-2840-8-15.

2.

Differences in effects of insulin glargine or pioglitazone added to oral anti-diabetic therapy in patients with type 2 diabetes: what to add--insulin glargine or pioglitazone?

Dorkhan M, Frid A, Groop L.

Diabetes Res Clin Pract. 2008 Dec;82(3):340-5. doi: 10.1016/j.diabres.2008.09.009. Epub 2008 Oct 15.

PMID:
18926586
3.

Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.

van der Meer RW, Rijzewijk LJ, de Jong HW, Lamb HJ, Lubberink M, Romijn JA, Bax JJ, de Roos A, Kamp O, Paulus WJ, Heine RJ, Lammertsma AA, Smit JW, Diamant M.

Circulation. 2009 Apr 21;119(15):2069-77. doi: 10.1161/CIRCULATIONAHA.108.803916. Epub 2009 Apr 6.

4.

Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes.

Dorkhan M, Magnusson M, Frid A, Grubb A, Groop L, Jovinge S.

J Intern Med. 2006 Aug;260(2):125-33.

5.

Effects of rosiglitazone on plasma brain natriuretic peptide levels and myocardial performance index in patients with type 2 diabetes mellitus.

Türkmen Kemal Y, Güvener Demirag N, Yildirir A, Atar A, Dogruk Unal A, Biyiklioglu Z.

Acta Diabetol. 2007 Sep;44(3):149-56. Epub 2007 Aug 26.

PMID:
17721754
6.

Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes.

Sambanis C, Tziomalos K, Kountana E, Kakavas N, Zografou I, Balaska A, Koulas G, Karagiannis A, Zamboulis C.

Acta Diabetol. 2008 Mar;45(1):23-30. Epub 2007 Sep 4.

PMID:
17768592
7.

Weight gain in type 2 diabetes mellitus.

Jacob AN, Salinas K, Adams-Huet B, Raskin P.

Diabetes Obes Metab. 2007 May;9(3):386-93.

PMID:
17391167
8.

Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital.

Hussein Z, Wentworth JM, Nankervis AJ, Proietto J, Colman PG.

Med J Aust. 2004 Nov 15;181(10):536-9.

PMID:
15540964
9.

Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.

Derosa G, Mereu R, Salvadeo SA, D'Angelo A, Ciccarelli L, Piccinni MN, Ferrari I, Gravina A, Maffioli P, Cicero AF.

Intern Med. 2009;48(5):265-71. Epub 2009 Mar 2.

10.

Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes.

Roden M, Mariz S, Brazzale AR, Pacini G.

J Intern Med. 2009 Apr;265(4):476-87. doi: 10.1111/j.1365-2796.2008.02040.x.

11.

[Assessment of left ventricular diastolic function with pioglitazone in type 2 diabetic patients].

Terui G, Goto T, Katsuta M, Aoki I.

J Cardiol. 2006 Nov;48(5):263-7. Japanese.

PMID:
17136821
12.

Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes.

Vinik AI, Zhang Q.

Diabetes Care. 2007 Apr;30(4):795-800. Epub 2007 Jan 26. Erratum in: Diabetes Care. 2007 Jun;30(6):1684.

PMID:
17259481
13.

Pioglitazone improves left ventricular diastolic function in patients with essential hypertension.

Horio T, Suzuki M, Suzuki K, Takamisawa I, Hiuge A, Kamide K, Takiuchi S, Iwashima Y, Kihara S, Funahashi T, Yoshimasa Y, Kawano Y.

Am J Hypertens. 2005 Jul;18(7):949-57.

PMID:
16053992
14.

The insulin sensitiser pioglitazone does not influence skin microcirculatory function in patients with type 2 diabetes treated with insulin.

Tooke JE, Elston LM, Gooding KM, Ball CI, Mawson DM, Piper J, Sriraman R, Urquhart R, Shore AC.

Diabetologia. 2006 May;49(5):1064-70. Epub 2006 Mar 1.

PMID:
16508777
15.
16.

Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction.

Giles TD, Miller AB, Elkayam U, Bhattacharya M, Perez A.

J Card Fail. 2008 Aug;14(6):445-52. doi: 10.1016/j.cardfail.2008.02.007. Epub 2008 May 27.

PMID:
18672190
17.

Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.

Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, Maffioli P, Cicero AF.

Metabolism. 2008 Nov;57(11):1552-7. doi: 10.1016/j.metabol.2008.06.010.

PMID:
18940393
18.

A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure.

Dargie HJ, Hildebrandt PR, Riegger GA, McMurray JJ, McMorn SO, Roberts JN, Zambanini A, Wilding JP.

J Am Coll Cardiol. 2007 Apr 24;49(16):1696-704. Epub 2007 Apr 6.

19.

Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure.

Granberry MC, Hawkins JB, Franks AM.

Am J Health Syst Pharm. 2007 May 1;64(9):931-6. Review.

PMID:
17468147
20.

Impact of glitazones on metabolic and haemodynamic parameters in patients with type 2 diabetes mellitus.

Chogtu B, Singh NP, Chawla S, Gupta U.

Singapore Med J. 2009 Apr;50(4):395-9.

Items per page

Supplemental Content

Write to the Help Desk